Cost-effectiveness of primary surgical versus primary medical management in the treatment of patients presenting with advanced glaucoma

被引:2
|
作者
Kernohan, Ashleigh [1 ]
Homer, Tara [1 ]
Shabaninejad, Hosein [1 ]
King, Anthony J. [2 ]
Hudson, Jemma [3 ]
Fernie, Gordon [4 ]
Azuara-Blanco, Augusto [5 ]
Burr, Jennifer [6 ]
Sparrow, John M. [7 ]
Garway-Heath, David [8 ]
Barton, Keith [8 ]
Norrie, John [9 ]
Maclennan, Graeme [4 ]
Vale, Luke [1 ,10 ]
机构
[1] Newcastle Univ, Populat Hlth Sci Inst, Newcastle Upon Tyne, Tyne & Wear, England
[2] Nottingham Univ Hosp, Dept Ophthalmol, Nottingham, England
[3] Univ Aberdeen, Hlth Serv Res Unit, Aberdeen, Scotland
[4] Univ Aberdeen, Ctr Healthcare Randomised Trials CHaRT, Hlth Serv Res Unit, Aberdeen, Scotland
[5] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland
[6] Univ St Andrews, Sch Med, St Andrews, Fife, Scotland
[7] Univ Hosp Bristol NHS Fdn Trust, Bristol Eye Hosp, Bristol, Avon, England
[8] Moorfields Eye Hosp NHS Fdn Trust, Natl Inst Hlth Res NIHR Biomed Res Ctr, London, England
[9] Univ Edinburgh, Usher Inst, Edinburgh Clin Trials Unit, Edinburgh, Midlothian, Scotland
[10] NIHR, NIHR Appl Res Collaborat North East & North Cumbr, Newcastle Upon Tyne, Tyne & Wear, England
关键词
Glaucoma; Treatment Medical; Treatment Surgery; OPEN-ANGLE GLAUCOMA; VISUAL-FIELD LOSS; IMPAIRMENT; VISION;
D O I
10.1136/bjo-2021-320887
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Synopsis Advanced glaucoma is associated with sight loss. This within-trial economic evaluation compares medical and surgical management strategies. At 2 years, medication appears more cost-effective though longitudinal outcomes are an important subject in future research. Background/aims Open angle glaucoma (OAG) is a progressive optic neuropathy. Approximately 25% of newly diagnosed patients with OAG present with advanced disease in at least one eye. The vision loss associated with OAG can lead to significant impacts on vision, quality of life and health care resources. The Treatment of Advanced Glaucoma Study is a randomised controlled trial comparing the effectiveness of primary surgical and medical management for newly diagnosed advanced patients with OAG. An economic evaluation was carried out to understand the costs and benefits of each strategy. Methods A cost utility analysis was carried out from a National Health Service perspective over a 2-year time horizon inclusive of patient costs. The primary outcome was patient health-related quality of life measured by the EQ-5D-5L, Health Utilities Index 3 (HUI3) and Glaucoma Utility Index (GUI). Results were expressed as incremental cost per QALY gained. Results Trabeculectomy was associated with higher costs and greater effect, the EQ-5D-5L results have an incremental cost per QALY of 45,456 pound. The likelihood of surgery being cost-effective at a 20 pound, 000, 30,000 pound and 50,000 pound QALY threshold is 0%, 12% and 56%, respectively. The results for the HUI3, GUI and inclusion of patient costs do not change the conclusions of the study. Conclusion This is the first study to evaluate management strategies for those presenting with advanced glaucoma. At a 2-year time horizon, medication is the more cost-effective approach for managing glaucoma. Future research can focus on the costs and benefits of the treatments over a longer time horizon.
引用
收藏
页码:1452 / 1457
页数:6
相关论文
共 50 条
  • [1] The willingness of patients presenting with advanced glaucoma to participate in a trial comparing primary medical vs primary surgical treatment
    P Leighton
    A J Lonsdale
    J Tildsley
    A J King
    Eye, 2012, 26 : 300 - 306
  • [2] The willingness of patients presenting with advanced glaucoma to participate in a trial comparing primary medical vs primary surgical treatment
    Leighton, P.
    Lonsdale, A. J.
    Tildsley, J.
    King, A. J.
    EYE, 2012, 26 (02) : 300 - 306
  • [3] Cost-Effectiveness Analysis of Surgical versus Medical Treatment of Prolactinomas
    Zygourakis, Corinna C.
    Imber, Brandon S.
    Chen, Rebecca
    Han, Seunggu J.
    Blevins, Lewis
    Molinaro, Annette
    Kahn, James G.
    Aghi, Manish K.
    JOURNAL OF NEUROLOGICAL SURGERY PART B-SKULL BASE, 2017, 78 (02) : 125 - 131
  • [4] Different strategies and cost-effectiveness in the treatment of primary open angle glaucoma
    Ting, Naomi S. J.
    Yim, James F. T. Li
    Ng, Jia Y.
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2014, 6 : 523 - 530
  • [5] COST-EFFECTIVENESS OF OMNI® SURGICAL SYSTEM VERSUS ISTENT INJECT® FOR THE TREATMENT OF PRIMARY OPEN-ANGLE GLAUCOMA IN THE UNITED STATES
    Longo, R.
    Ghinelli, F.
    Morris, L.
    Liu, J.
    Dickerson, J.
    Patel, C.
    Mader, G.
    Nguyen, D.
    Canter, L. B.
    VALUE IN HEALTH, 2022, 25 (12) : S134 - S134
  • [6] Cost-Effectiveness of Neoadjuvant Chemotherapy versus Primary Surgery in Elderly Patients with Advanced Ovarian Cancer
    Poonawalla, Insiya B.
    Lairson, David R.
    Chan, Wenyaw
    Piller, Linda B.
    Du, Xianglin L.
    VALUE IN HEALTH, 2015, 18 (04) : 387 - 395
  • [7] Cost-effectiveness of primary PTCA versus thrombolysis
    Brodie, BR
    JOURNAL OF INVASIVE CARDIOLOGY, 1998, 10 : 11A - 15A
  • [8] The cost-effectiveness of three strategies for the surgical treatment of symptomatic primary hyperparathyroidism
    Baliski, Chris
    Nosyk, Bohdan
    Melck, Adrienne
    Bugis, Samuel
    Rosenberg, Frances
    Anis, Aslam H.
    ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (10) : 2653 - 2660
  • [9] The Cost-Effectiveness of Three Strategies for the Surgical Treatment of Symptomatic Primary Hyperparathyroidism
    Chris Baliski
    Bohdan Nosyk
    Adrienne Melck
    Samuel Bugis
    Frances Rosenberg
    Aslam H. Anis
    Annals of Surgical Oncology, 2008, 15 : 2653 - 2660
  • [10] Cost-effectiveness of Phacoemulsification Versus Combined Phacotrabeculectomy for Treating Primary Angle Closure Glaucoma
    Chan, Poemen P.
    Li, Emmy Y.
    Tsoi, Kelvin K. F.
    Kwong, Yolanda Y.
    Tham, Clement C.
    JOURNAL OF GLAUCOMA, 2017, 26 (10) : 911 - 922